Hisamitsu Pharmaceutical : Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
July 30, 2023
Share
This material is an English translation of the press release announced on Jul. 31, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.
Jul. 31, 2023
Notice regarding Determination of Details of Issuance of Stock Compensation-
Type Share Options (Stock Acquisition Rights)
The Company is pleased to announce that the undetermined matters regarding the stock compensation- type share options (stock acquisition rights), which were resolved at the Board of Directors held on July 13, 2023, have been determined today as follows.
Total number of stock acquisition rights: 228 rights
Amount to be paid for stock acquisition rights:
377,000 yen per stock acquisition right (3,770 yen per share)
(Note) The above amount is calculated in accordance with the Black-Scholes model based on the closing price of the Company's shares on the Tokyo Stock Exchange on the date of allocation of the stock acquisition rights. The compensation claim held by the person who received an allocation against the Company shall be offset against the payment obligation of the amount to be paid for the stock acquisition rights.
3. Persons eligible for the allocation of stock acquisition rights, the number of such persons, and the number of stock acquisition rights to be allocated
Persons eligible for the allocation
Number of
Number of stock acquisition rights
persons
to be allocated
Directors of the Company (excluding
6 persons
228 rights
outside directors)
Attachments
Original Link
Original Document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 31 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2023 02:51:07 UTC.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
HISAMITSU PHARMACEUTICAL CO., INC. 
